Peter Ballard

5.1k total citations · 1 hit paper
45 papers, 1.4k citations indexed

About

Peter Ballard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Organic Chemistry. According to data from OpenAlex, Peter Ballard has authored 45 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 12 papers in Organic Chemistry. Recurrent topics in Peter Ballard's work include HER2/EGFR in Cancer Research (13 papers), Lung Cancer Treatments and Mutations (13 papers) and Quinazolinone synthesis and applications (10 papers). Peter Ballard is often cited by papers focused on HER2/EGFR in Cancer Research (13 papers), Lung Cancer Treatments and Mutations (13 papers) and Quinazolinone synthesis and applications (10 papers). Peter Ballard collaborates with scholars based in United Kingdom, United States and France. Peter Ballard's co-authors include Mireille Cantarini, Kathryn Pickup, Darren A.E. Cross, James Yates, James Chih‐Hsin Yang, Pasi A. Jänne, Angela Jordan, Zhenfan Yang, Katarina Varnäs and Matthew Grist and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Clinical Cancer Research.

In The Last Decade

Peter Ballard

45 papers receiving 1.3k citations

Hit Papers

Preclinical Comparison of Osimertinib with Other EGFR-TKI... 2016 2026 2019 2022 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
    2016 523 citations Peter Ballard, James Yates et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Ballard United Kingdom 19 704 670 431 254 112 45 1.4k
Ana Ruiz-Garcı́a United States 23 952 1.4× 806 1.2× 622 1.4× 93 0.4× 95 0.8× 65 2.0k
Yiqun Li China 9 681 1.0× 465 0.7× 866 2.0× 242 1.0× 52 0.5× 25 1.7k
Philip Lienau Germany 21 468 0.7× 204 0.3× 766 1.8× 433 1.7× 79 0.7× 37 1.4k
Hua Xiang China 25 389 0.6× 191 0.3× 851 2.0× 436 1.7× 46 0.4× 133 2.0k
Jörg Czech Germany 16 495 0.7× 163 0.2× 712 1.7× 222 0.9× 45 0.4× 33 1.3k
Audrey Thomas‐Schoemann France 19 550 0.8× 280 0.4× 415 1.0× 61 0.2× 60 0.5× 54 1.1k
Taoufik Ouatas United States 23 337 0.5× 463 0.7× 866 2.0× 89 0.4× 99 0.9× 38 1.8k
Milin Acharya United States 19 637 0.9× 281 0.4× 934 2.2× 74 0.3× 224 2.0× 36 1.9k
Edna F. Choo United States 24 797 1.1× 135 0.2× 1.0k 2.3× 151 0.6× 286 2.6× 54 1.9k
Tohru Ohmori Japan 26 1.3k 1.8× 671 1.0× 1.1k 2.6× 127 0.5× 35 0.3× 82 2.2k

Countries citing papers authored by Peter Ballard

Since Specialization
Citations

This map shows the geographic impact of Peter Ballard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ballard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ballard more than expected).

Fields of papers citing papers by Peter Ballard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ballard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ballard. The network helps show where Peter Ballard may publish in the future.

Co-authorship network of co-authors of Peter Ballard

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ballard. A scholar is included among the top collaborators of Peter Ballard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ballard. Peter Ballard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hewitt, Philip, et al.. (2024). Absence of developmental and reproductive toxicity in rats, rabbits, and zebrafish embryos exposed to antimalarial drug cabamiquine. Birth Defects Research. 116(8). e2389–e2389. 1 indexed citations
2.
Friedrich, Lukas, Sang‐Kyu Park, Peter Ballard, et al.. (2023). Metabolism of (R)‐Praziquantel versus the Activation of a Parasite Transient Receptor Potential Melastatin Ion Channel. ChemMedChem. 18(18). e202300140–e202300140. 5 indexed citations
3.
Ballard, Peter, et al.. (2023). A unique soft tissue injury with devastating delayed consequences: A video case report. SHILAP Revista de lepidopterología. 4(2). e12909–e12909. 1 indexed citations
4.
Ballard, Peter, James Yates, Zhenfan Yang, et al.. (2016). Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clinical Cancer Research. 22(20). 5130–5140. 523 indexed citations breakdown →
5.
Yates, James, Susan Ashton, Darren A.E. Cross, et al.. (2016). Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic–Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104. Molecular Cancer Therapeutics. 15(10). 2378–2387. 34 indexed citations
6.
Ballard, Peter, Nigel Bean, & Joshua V. Ross. (2016). The probability of epidemic fade-out is non-monotonic in transmission rate for the Markovian SIR model with demography. Journal of Theoretical Biology. 393. 170–178. 7 indexed citations
7.
Dickinson, Paul A., Mireille Cantarini, Paul Frewer, et al.. (2016). Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor. Drug Metabolism and Disposition. 44(8). 1201–1212. 105 indexed citations
8.
Bradbury, Robert H., Neil J. Hales, Alfred A. Rabow, et al.. (2011). Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer. Bioorganic & Medicinal Chemistry Letters. 21(18). 5442–5445. 36 indexed citations
9.
Barlaam, Bernard, David Acton, Peter Ballard, et al.. (2008). Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 18(6). 1799–1803. 10 indexed citations
10.
Ducray, Richard, et al.. (2007). Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(3). 959–962. 70 indexed citations
11.
Ballard, Peter, Bernard Barlaam, Robert H. Bradbury, et al.. (2007). Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 17(22). 6326–6329. 23 indexed citations
12.
Ballard, Peter, Robert H. Bradbury, Craig S. Harris, et al.. (2006). Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimisation of potency and in vivo pharmacokinetics. Bioorganic & Medicinal Chemistry Letters. 16(18). 4908–4912. 29 indexed citations
13.
Hennequin, Laurent, Peter Ballard, Bénédicte Delouvrié, et al.. (2006). Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: Synthesis and structure–activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(10). 2672–2676. 22 indexed citations
14.
Ballard, Peter, Robert H. Bradbury, Laurent Hennequin, et al.. (2005). 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 15(19). 4226–4229. 31 indexed citations
15.
Ballard, Peter, Robert H. Bradbury, Craig S. Harris, et al.. (2005). Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket. Bioorganic & Medicinal Chemistry Letters. 16(6). 1633–1637. 31 indexed citations
16.
17.
Ballard, Peter, David E. Leahy, & Malcolm Rowland. (2000). Prediction of in vivo tissue distribution from in vitro data 1. Experiments with markers of aqueous spaces.. Pharmaceutical Research. 17(6). 660–663. 22 indexed citations
18.
Blakey, Graham, Peter Ballard, David E. Leahy, & Malcolm Rowland. (1999). Development of an assay for the extraction and quantification of nine 5-n-alkyl-5-ethyl barbituric acids in various rat tissues. Journal of Pharmaceutical and Biomedical Analysis. 18(6). 927–938. 3 indexed citations
19.
Ballard, Peter, et al.. (1996). The development and performance of a radioimmunoassay for the analysis of ZM 213,689, the major metabolite of meropenem—a carbapenem antibiotic—in plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 14(4). 409–417. 5 indexed citations
20.
Ballard, Peter, Michael Malone, & Brian K. Law. (1994). The use of competitive displacement agents to resolve albumin binding problems observed during the development of a radioimmunoassay for ICI 215001. Journal of Pharmaceutical and Biomedical Analysis. 12(1). 47–52. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ana Ruiz-Garcı́a Breakdown of academic impact, for papers by Yiqun Li Breakdown of academic impact, for papers by Philip Lienau Breakdown of academic impact, for papers by Hua Xiang Breakdown of academic impact, for papers by Jörg Czech Breakdown of academic impact, for papers by Audrey Thomas‐Schoemann Breakdown of academic impact, for papers by Taoufik Ouatas Breakdown of academic impact, for papers by Milin Acharya Breakdown of academic impact, for papers by Edna F. Choo Breakdown of academic impact, for papers by Tohru Ohmori
Rankless by CCL
2026